Download PDF
Thromb Haemost 1972; 27(03): 535-542
DOI: 10.1055/s-0038-1649393
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Effect of Several Tissue Thromboplastins on the Activation of the Abnormal Factor X (Factor X Friuli)

A Girolami
1   University of Padua Medical School, Institute of “Semeiotica Medica”, Padua, Italy
,
M Lazzarin
1   University of Padua Medical School, Institute of “Semeiotica Medica”, Padua, Italy
,
G Molaro
1   University of Padua Medical School, Institute of “Semeiotica Medica”, Padua, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

    Permissions and Reprints

Summary

The effect of several tissue thromboplastins on the abnormal factor X (factor X Friuli) has been investigated.

The prothrombin time varied between 33.6 and 69 sec. The prothrombin time percentile values (saline dilution curve and Quick’s formula for citrated plasma) varied between 6.6 and 22% and between 10.9 and 32.8%, respectively. The prothrombin time patient/normal ratio varied between 2.24 and 4.43.

The factor X level varied between 3.5 and 20% of normal.

Significant correlations were found to exist between the percentile factor X level and the prothrombin time in seconds, the percentile prothrombin time values and the prothrombin time patient/normal ratio. Thromboplastins of human origin yielded the lowest factor X values namely 5% thereby appearing to be practically “inert” with regard to the abnormal factor X. Thromboplastins obtained from rabbit lung on the contrary yielded the highest values, namely 15.3%. Thromboplastins obtained from simian or rabbit brain gave values intermediate between these two extremes.

 

  • References

  • 1 Bachmann F, Duckert F, Flückiger P. The Stuart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. (Stuttg) 02: 24 1958;
    PubMedGoogle Scholar
  • 2 Biggs R, Denson K. W. Standardisation of the one-stage prothrombin time for the control of anticoagulant therapy. Brit. Med. J I: 84 1967;
    PubMedGoogle Scholar
  • 3 Caldwell M. J, Priest E. M. A different concept of prothrombin time control for anti- coagulative therapy. Amer. Heart J 56: 637 1958;
    PubMedGoogle Scholar
  • 4 Denson K. W. Tissue extracts and their sensitivity to factor VII and factor X. Thrombos. Diathes. haemorrh. (Stuttg) 11: 146 1964;
    PubMedGoogle Scholar
  • 5 Denson K. W. The specific assay of Prower-Stuart factor and factor VII. Acta haemat. (Basel) 25: 105 1961;
    CrossrefPubMedGoogle Scholar
  • 6 Girolami A, Molaro G, Lazzarin M, Scarpa R, Brunetti A. Congenital haemorrhagic condition similar but not identical to factor X deficiency. A hemorrhagic state due to an abnormal factor X ? Scand. J. Haemat 07: 91 1970;
    PubMedGoogle Scholar
  • 7 Girolami A, Molaro G, Lazzarin M, Scarpa R, Brunetti A. A “new” congenital hemorrhagic condition due to the presence of an abnormal factorX (factor X Friuli): study of 2 large kindred. Brit. J. Haemat 19: 179 1970;
    CrossrefPubMedGoogle Scholar
  • 8 Girolami A, Lazzarin M, Brunetti A, Scarpa R. Further studies on the abnormal factor X (factor X Friuli) coagulation disorder: a report of another family. Blood 37: 534 1971;
    PubMedGoogle Scholar
  • 9 Girolami A, Molaro G, Orazi B. L’ereditarieta della coagulopatia da fattore X abnorme (fattore X Friuli). Policlinico, Sez. med 57: 103 1970;
    PubMedGoogle Scholar
  • 10 Girolami A, Brunetti A, Scarpa R. Unpublished observations.
    PubMed
  • 11 Girolami A, Molaro G, Lazzarin M. Unpublished observations.
    PubMed
  • 12 Irsigler K, Lechner K, Deutsch E. Studies on tissue thromboplastin. II. Species specificity. Thrombos. Diathes. haemorrh. (Stuttg) 14: 17 1965;
    PubMedGoogle Scholar
  • 13 Miale J. B, Lafond D. J. 1963 Prothrombin time test survey, College of American pathologists, standards Committee, subcommittee on coagulation. Amer. J. clin. Path 47: 40 1963;
    PubMedGoogle Scholar
  • 14 Miale J. B, Lafond D. Prothrombin time standardization. Amer. J. clin. Path 52: 154 1969;
    PubMedGoogle Scholar
  • 15 Poller L. A national standard for anticoagulant therapy. Lancet I: 491 1967;
    PubMedGoogle Scholar
  • 16 Poller L, Thomson J. M. National survey of value of plasma standards for anticoagulant therapy. Brit. Med. J II: 88 1968;
    PubMedGoogle Scholar
  • 17 Quick A. J. The physiology and pathology of hemostasis. Lea and Febiger; Philadelphia: 1961
    Google Scholar
  • 18 Quick A. J. Thromboplastin as a reagent. Thrombos. Diathes. haemorrh. (Stuttg) 23: 585 1970;
    PubMedGoogle Scholar
  • 19 Rodman T, Pastor B. H, Hoxter B. L. Problems encountered in the laboratory control of anticoagulant therapy with the one-stage determination of prothrombin complex activity. Amer. J. Med 31: 555 1961;
    CrossrefPubMedGoogle Scholar
  • 20 Shapiro S. Comparison of thromboplastic activity of lyophilized preparations of thromboplastin. Amer. J. Med. Path 33: 220 1960;
    PubMedGoogle Scholar
  • 21 Verstraete M, Clarke P. A, Wright I. S. Use of different tissue thromboplastins in the control of anticoagulant therapy. Circulation 16: 213 1957;
    CrossrefPubMedGoogle Scholar
  • 22 Verstraete M, Clarke P. A, Wright I. S. Evaluation of prothrombin time performed with different thromboplastins. Acta med. scand 163: 105 1959;
    PubMedGoogle Scholar